Venable, Sateria R.
Al-Hendy, Ayman
Funding for this research was provided by:
Pfizer Inc
Article History
Received: 15 February 2023
Accepted: 26 June 2023
First Online: 12 August 2023
Change Date: 27 September 2023
Change Type: Update
Change Details: This article was revised due to update in funding note.
Declarations
:
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
: Ayman Al-Hendy has consulted for AbbVie, Bayer, Myovant Sciences, and ObsEva; received research support from the National Institutes of Health (R01 ES 028615–01, R01HD 087417, R01 HD 094378, R01 HD 094380, R01 HD 10036701, U54 MD 007602); and holds a patent for methods for novel diagnostics and therapeutics for uterine sarcoma (US patent no. 9,790,562 B2). Sateria Venable has consulted for AbbVie, Bayer, Myovant Sciences and ObsEva.